Table 3.
Aortic Z score
| Placebo | Irbesartan | Difference (95% CI) | p value | ||
|---|---|---|---|---|---|
| Change in aortic Z score (per year), mean (95% CI) | 0·15 (0·08 to 0·22) | 0·05 (−0·02 to 0·11) | −0·10 (−0·19 to −0·01) | 0·035 | |
| Aortic Z score | |||||
| Baseline, mean (SD); n | 3·28 (2·10); 88 | 3·21 (2·00); 104 | .. | .. | |
| 1 year, mean (95% CI), n | 3·44 (3·10 to 3·77), 84 | 2·96 (2·63 to 3·30), 93 | −0·47 (−0·74 to −0·20) | 0·0006 | |
| 2 years, mean (95% CI), n | 3·53 (3·16 to 3·90), 76 | 3·11 (2·75 to 3·47), 84 | −0·42 (−0·74 to −0·10) | 0·010 | |
| 3 years, mean (95% CI), n | 3·63 (3·26 to 4·00), 71 | 3·22 (2·86 to 3·59), 78 | −0·41 (−0·73 to −0·08) | 0·013 | |
| 4 years, mean (95% CI), n | 3·72 (3·30 to 4·14), 57 | 3·18 (2·76 to 3·60), 56 | −0·54 (−0·98 to −0·10) | 0·016 | |
| 5 years, mean (95% CI), n | 4·38 (3·80 to 4·97), 28 | 3·94 (3·35 to 4·52), 28 | −0·45 (−1·14 to 0·25) | 0·21 | |
Comparisons are made between groups at each timepoint. At the final follow-up visit the majority of patients had not reached 5 years of study participation, which accounts for the sharp decrease in numbers available for follow-up between year 4 and 5.